It appears from the filing receipt of this application that Claims 9 to 13 inclusive have not been entered as being in improper multiple dependent form. Applicant has therefore amended claims 9 to 13 placing them in proper form by the addition of claims 15 to 18 for the Examiner's review.

Further to the amendments to the claims outlined above, Applicant has re-calculated the filing fees for a large entity for the claim set as amended and encloses a cheque in payment for this re-calculation.

The fees for a large entity required for the above-identified amended claim set are: $918.00 for the excess claim fee for 51 additional dependent claims beyond that which is allowed for in the base filing fee, $270.00 for multiple dependent claims and $710.00 for the base filing fee of a large entity totaling $1,898.00. As Applicant has already paid $490.00 upon filing the application on March 16. 2001, Applicant encloses a cheque in the amount of $1,408.00 USD made payable to "The Commissioner of Patent" which is the difference after the re-calculation.

In view of the above submissions, Applicant respectfully submits that the amended claims in the Application are clearly allowable over the prior art, and full reconsideration is requested. No new matter has been added.

Attached hereto as Exhibit A (pages 8 to 11 of this amendment) is a marked-up version of the changes made to the claims by the present amendment. The attached pages are entitled **"EXHIBIT A – CLAIMS WITH MARKINGS TO SHOW CHANGES".**

Also attached hereto as Exhibit B (pages 12 to 15 of this amendment) are four sheets that contains a clean set of all pending claims following entry of

this amendment. These sheets are entitled **"EXHIBIT B – CLEAN SET OF ALL PENDING CLAIMS FOLLOWING ENTRY OF THE PRESENT AMENDMENT"**. All of the currently pending claims are consolidated in this list for the convenience of the Examiner.

Should the Examiner have any questions he/she is respectfully requested to contact Neil H. Hughes at (905) 771-6414 at his/her convenience.

Respectfully submitted,



Neil H. Hughes, P.Eng.
Registration No. 33,636
Agent for the Applicant

NHH:mse
Enclosures

EXHIBIT A

CLAIMS WITH MARKINGS TO SHOW CHANGES

1. A process of making a solid pharmaceutical composition comprising moexipril magnesium, said process comprising the step of reacting moexipril or an acid addition salt thereof with an alkaline magnesium compound in the presence of a solvent so as to convert most or all of the moexipril or moexipril acid addition salt to moexipril magnesium.

2. (Amended) [A] The process of Claim 1 comprising the steps of:

i) a [A]dding the moexipril or acid addition salt thereof and the alkaline magnesium compound to solvent and mixing in the liquid state;

ii) e [E]vaporating the solvent to obtain a dried material, and

iii) f [F]urther processing the dried material into the solid pharmaceutical composition.

3. (Amended) [A] The process of Claim 2 wherein, before the solvent is evaporated, the liquid is filtered to remove unreacted alkaline magnesium compound.

4. (Amended) [A] The process of Claim 2 or 3 wherein the solvent is evaporated by spray-drying.

5. (Amended) [A] The process of Claim 1 comprising the steps of:

i) adding the moexipril or acid addition salt thereof and the alkaline magnesium compound to solvent;

ii) using the resultant solution or suspension to wet granulate other excipients to obtain a wet mass;

iii) drying the wet mass to obtain a dried mass; and

iv) further processing the dried mass into the solid pharmaceutical composition.

6. (Amended) [A] The process of Claim 1 comprising the steps of:

i) adding the alkaline magnesium compound to solvent;

ii) using the resulting solution or suspension to wet granulate a mixture of the moexipril or acid addition salt thereof and one or more excipients to obtain a wet mass;

iii) drying the wet mass to obtain a dried mass; and

iv) further processing the dried mass into the solid pharmaceutical composition.

7. (Amended) [A] The process of Claim 1 comprising the steps of:

i) adding the moexipril or acid addition salt thereof to solvent;

ii) using the resultant solution or suspension to wet granulate a mixture of the alkaline magnesium compound and one or more other excipients to obtain wet mass;

iii) drying the wet mass to obtain a dried mass, and

iv) further processing the dried mass into the solid pharmaceutical composition.

8. (Amended) [A] The process of Claim 1 comprising the steps of:

i) mixing the moexipril or acid addition salt thereof and alkaline magnesium compound with one or more other excipients;

ii) adding a solvent and mixing to obtain a wet mass;

iii) drying the wet mass to obtain a dry mass; and

iv) further processing the dried mass into the solid pharmaceutical composition.

9. (Amended) [A] The process of any one of Claims [1 to 8] 1, 2, 3, 5, 6, 7, or 8 where the solvent is selected from a group of solvents comprising water, an organic solvent, acetone, or combinations thereof.

10. (Amended) [A] The process of any one of Claims [1 to 8] 1, 2, 3, 5, 6, 7, or 8 wherein the moexipril or acid addition salt thereof is moexipril hydrochloride.

11. (Amended) [A] The process of any one of Claims [1 to 8] 1, 2, 3, 5, 6, 7, or 8 wherein the alkaline magnesium compound is selected from the group of compounds comprising magnesium hydroxide, magnesium oxide, magnesium carbonate, or the magnesium salt of a weak acid.

12. (Amended) [A] The process of any one of Claims [1 to 8] 1, 2, 3, 5, 6, 7, or 8 wherein the percentage of the moexipril or acid addition salt converted to moexipril magnesium is substantially greater than about 80%.

13. (Amended) [A] The process of [any of] Claim 12 wherein the percentage of the moexipril or acid addition salt thereof converted to moexipril magnesium is substantially greater than 90%.

14. A solid pharmaceutical composition comprising moexipril magnesium.

Please add the following claims.

15. The process of Claim 4 where the solvent is selected from a group of solvents comprising water, an organic solvent, acetone, or combinations thereof.

16. The process of Claim 4 wherein the moexipril or acid addition salt thereof is moexipril hydrochloride.

17. The process of Claim 4 wherein the alkaline magnesium compound is selected from the group of compounds comprising magnesium hydroxide, magnesium oxide, magnesium carbonate, or the magnesium salt of a weak acid.

18. The process of Claim 4 wherein the percentage of the moexipril or acid addition salt converted to moexipril magnesium is substantially greater than about 80%.